The Epidermolysis Bullosa drugs in development market research report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Epidermolysis Bullosa. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued products.
GlobalData tracks 52 drugs in development for Epidermolysis Bullosa by 48 companies/universities/institutes. The top development phase for Epidermolysis Bullosa is preclinical with 19 drugs in that stage. The Epidermolysis Bullosa pipeline has 50 drugs in development by companies and two by universities/ institutes. Some of the companies in the Epidermolysis Bullosa pipeline products market are: Phoenicis Therapeutics, GeCell Therapeutics and Aegle Therapeutics.
The key targets in the Epidermolysis Bullosa pipeline products market include Collagen Alpha 1(VII) Chain (Long Chain Collagen or COL7A1), Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).
The key mechanisms of action in the Epidermolysis Bullosa pipeline product include Collagen Alpha 1(VII) Chain (Long Chain Collagen or COL7A1) Activator with ten drugs in Pre-Registration. The Epidermolysis Bullosa pipeline products include ten routes of administration with the top ROA being Topical and 13 key molecule types in the Epidermolysis Bullosa pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Epidermolysis Bullosa overview
Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin; deformity or loss of fingernails and toenails; internal blistering including on the throat, esophagus, upper airway, stomach, intestines, and urinary tract; skin thickening on palms and soles of the feet (hyperkeratosis); and scalp blistering, scarring, and hair loss (scarring alopecia). Treatment includes antibiotics and surgery.
For a complete picture of Epidermolysis Bullosa’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
